The Chemours Company offers high performance chemicals in North America, Asia Pacific, Europe, the Middle East, Africa and Latin America. The company is headquartered in Wilmington, Delaware.
305 articles
Chemours Company faces a securities class action lawsuit alleging misleading statements regarding Opteon aftermarket demand by executives. Eligible investors purchasing shares during the specified per
Levi & Korsinsky alerts Chemours investors to the December 7, 2026 deadline for a securities class action alleging overstated Opteon refrigerant demand caused a stock drop. Investors with losses betwe
Kahn Swick & Foti LLC reminds Chemours investors of a securities class action lawsuit deadline of December 7, 2026, citing alleged nondisclosure regarding an 18% stock drop driven by refrigerant chann
Chemours Co declared a Q4 2026 cash dividend of $0.0875 per share, payable on December 15, 2026, to stockholders of record as of November 16, 2026.
The Chemours Company declared a quarterly cash dividend of $0.0875 per share, payable on December 15, 2026. Analysts view this routine declaration as reinforcing the company's capital return strategy.
Chemours faces a class action lawsuit alleging overstated Opteon demand compromised financial guidance. Investors purchasing securities between Feb and Aug 2026 are urged to join the case.
SBS Law announced a class action lawsuit against Chemours for alleged securities fraud regarding Opteon demand and 2026 guidance, urging eligible shareholders to join before the December 2026 deadline
Chemours achieved a 57% reduction in Scope 1 and 2 emissions since 2018, targeting 60% by 2030 via energy efficiency and renewables. Additionally, its refrigerant portfolio transition prevented over 8
A securities fraud class action has been filed against Chemours following an 18.63% stock drop linked to alleged misrepresentations of Opteon product demand. Investors have until December 7, 2026, to
Robbins LLP is soliciting Chemours shareholders for a class action lawsuit alleging overstated Opteon demand caused unreliable 2026 guidance and a significant stock price decline.
Levi & Korsinsky, LLP filed a securities fraud class action lawsuit against The Chemours Company, alleging misrepresentation of Opteon refrigerant sales demand. The suit claims this led to an 18.63% s
Chemours Co. faces a securities class action lawsuit alleging overstated demand for Opteon products. Investors who purchased shares between February and August 2026 have until December 7, 2026, to see
Chemours Co. faces a securities class action lawsuit alleging undisclosed oversupply in the refrigerant aftermarket, resulting in an 18.6% stock drop and reduced EBITDA guidance. Investors have until
A law firm filed a class action against Chemours, alleging overstated demand for its Opteon products led to unreliable financial guidance. Investors buying securities during the specified period are u
Chemours investors must file by December 7, 2026, to join a securities fraud lawsuit alleging misleading claims about Opteon demand and financial guidance. The case follows a sharp stock decline after
SueWallSt.com notifies Chemours investors of a December 7, 2026 deadline for a class action lawsuit alleging misleading statements on Opteon refrigerant demand and 2026 financial guidance.
Chemours Co faces a securities class action lawsuit alleging fraud over overstated Opteon product demand and unreliable 2026 financial guidance. Investors are being encouraged to seek recovery for los
Robbins LLP urges Chemours investors with losses between February and August 2026 to contact the firm regarding a class action lawsuit alleging overstated Opteon demand led to unreliable financial gui
Argus Research lowered its price target for Chemours Co to $12.00, reflecting market conditions for its industrial and specialty chemical solutions. The report, dated October 21, 2026, notes the curre
Chemours obtained injunctions against four firms for infringing patents on hydrofluoroolefin (HFO) refrigerant blends, reinforcing its commitment to protecting advanced refrigerant technology investme
Chemours Co. announced it will release its third-quarter 2026 financial results after market close on November 2, 2026. A public conference call to discuss these results will follow at 8:00 a.m. Easte
Chemours Co. will release its third-quarter 2026 financial results after market close on November 2, 2026, followed by a public webcast conference call at 8:00 a.m. EST on November 3, 2026.
Levi & Korsinsky LLP filed a securities class action against Chemours Co., alleging misleading statements on Opteon demand and EBITDA guidance between February and August 2026. Investors with losses d
Chemours faces a securities class action lawsuit alleging misrepresentation of Opteon refrigerant sales and financial guidance, causing excess inventory and a share price drop after its Q2 2026 report
Chemours faces securities fraud class action alleging overstated refrigerant demand, resulting in an EBITDA cut and 18.63% stock decline. Investors purchasing shares between February and August 2026 h
Chemours reduced full-year EBITDA guidance citing Opteon refrigerant oversupply, causing a stock drop. Moore Law PLLC is encouraging investors to contact the firm for potential monetary damages.
Moore Law PLLC is inviting Chemours investors to contact them after the company lowered full-year EBITDA guidance and disclosed excess Opteon refrigerant inventory, causing stock drops and rating down
Moore Law PLLC is investigating Chemours after an 18.63% stock drop and guidance cut linked to excess Opteon inventory and lowered EBITDA outlook.
Chemours Co. faces a securities class action alleging overstated Opteon demand and poor financial guidance caused a stock drop. Investors may join the suit before the December 7, 2026 deadline.
The Law Offices of Frank R. Cruz filed a securities fraud class action against Chemours after its stock fell 18.63% due to revised guidance on Opteon product demand. Investors have until December 7, 2
ChemBrief